• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down0.32% Nasdaq Down0.62%

    Tetraphase Pharmaceuticals, Inc. (TTPH)

    5.60 Down 0.05(0.88%) Apr 29, 4:00PM EDT
    |After Hours : 5.60 0.00 (0.00%) Apr 29, 4:35PM EDT
    ProfileGet Profile for:
    Tetraphase Pharmaceuticals, Inc.
    480 Arsenal Street
    Suite 110
    Watertown, MA 02472
    United States - Map
    Phone: 617-715-3600
    Fax: 617-926-3557
    Website: http://www.tphase.com

    Index Membership:N/A
    Industry:Drugs - Generic
    Full Time Employees:69

    Business Summary 

    Tetraphase Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. Its lead product candidate includes eravacycline, an intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant Gram-negative infections. The company has completed a Phase 3 clinical trial of eravacycline with intravenous administration for the treatment of complicated intra-abdominal infections; and a second Phase 3 clinical trial of eravacycline for the treatment of complicated urinary tract infections with intravenous-to- oral transition therapy. It is also developing TP-271, a preclinical compound for respiratory diseases caused by bacterial biothreat pathogens; and TP-6076, a preclinical Gram-negative program for multidrug-resistant Gram-negative infections. In addition, the company engages in the discovery and development of additional antibiotics for the treatment of unmet medical needs, including multidrug-resistant Gram-negative bacteria. Tetraphase Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Watertown, Massachusetts.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Tetraphase Pharmaceuticals, Inc.

    Corporate Governance 
    Tetraphase Pharmaceuticals, Inc.’s ISS Governance QuickScore as of Apr 1, 2016 is 7. The pillar scores are Audit: 2; Board: 5; Shareholder Rights: 8; Compensation: 6.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Mr. Guy MacDonald B.Sc, 57
    Chief Exec. Officer, Pres and Director
    Dr. Patrick T. Horn M.D., Ph.D., 61
    Chief Medical Officer
    Mr. Christopher Watt , 51
    Principal Financial Officer and VP of Fin.
    Dr. Jacques Dumas Ph.D., 50
    Chief Scientific Officer
    Ms. Maria D. Stahl , 45
    Sr. VP and Gen. Counsel
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders